GlassScriptPhysician profile
Patrick W Dixon
NPI 1417308313
$2,573.61
in general payments reported to CMS, 2019-2025
25 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $1,398 · 2023: $361 · 2024: $365 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $1,232.06 | 2022 | |
| Livanova USA, INC. | $291.65 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Teva Pharmaceuticals USA, INC. | $285.39 | 2021-2025 | Uzedy, Austedo Xr, Ajovy |
| Tempus Ai, INC | $148.51 | 2024 | |
| Vanda Pharmaceuticals INC. | $93.18 | 2024-2025 | Fanapt |
| Abbott Laboratories | $77.79 | 2021-2022 | |
| Nevro Corp. | $66.81 | 2021-2023 | Senza |
| Neuronetics, INC. | $44.52 | 2022-2025 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.95 | 2024-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $31.66 | 2023-2025 | Belbuca |
| Lundbeck LLC | $30.98 | 2024 | Rexulti |
| Amgen INC. | $25.82 | 2021-2022 | |
| Almatica Pharma LLC | $25.14 | 2022 | |
| Abbvie INC. | $19.13 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.34 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.04 | 2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $16.20 | 2024 | Spravato |
| Allergan, INC. | $15.93 | 2021 | |
| Tris Pharma INC | $15.77 | 2025 | Onyda Xr |
| Si-Bone, INC. | $14.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.62 | 2021 | |
| Uswm, LLC | $14.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.68 | 2023 | |
| Lilly USA, LLC | $12.70 | 2023 | Emgality |
| Corium, LLC | $7.18 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.